Kesimpta Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kesimpta market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth in the historic period can be attributed to the expansion of healthcare access, advances in biological therapies, increasing prevalence of multiple sclerosis, approval of kesimpta by regulatory authorities, and improving understanding of multiple sclerosis.

Market growth during the forecast period is expected to be driven by strong support from healthcare providers, rising demand for subcutaneous injections, growing awareness of multiple sclerosis (MS) and available treatment options, the increasing prevalence of MS, and the approval of new indications. Key trends in the forecast period include advancements in MS treatment, expansion into emerging markets, a shift toward self-administration, continued regulatory approvals and expansions, and a greater focus on personalized medicine.

The increasing prevalence of multiple sclerosis (MS) is expected to drive the growth of the kesimpta market. MS is a chronic autoimmune disease that affects the central nervous system, leading to nerve fiber degeneration and symptoms such as muscle weakness, vision problems, and cognitive impairment. The rise in MS prevalence is due to factors such as improved diagnostic techniques, heightened awareness, and better reporting systems. Kesimpta, a treatment for relapsing forms of MS, works by targeting B-cells to reduce relapses and slow disease progression. For instance, data from Public Health Scotland in July 2023 revealed that newly diagnosed MS patients in Scotland increased by 87.2% in 2022, which highlights the growing number of individuals requiring treatment. As the prevalence of MS continues to rise, kesimpta's market demand is expected to increase significantly.

The rise in healthcare expenditure is key factor driving the growth of the kesimpta market. Healthcare expenditure encompasses spending on services such as hospital care, pharmaceuticals, and public health programs. As healthcare costs rise due to an aging population, chronic diseases, and advancements in medical technology, the demand for effective treatments such as Kesimpta is expected to increase. For example, in May 2024, the Office for National Statistics in the UK reported a 5.6% rise in total healthcare expenditure from 2022 to 2023. With a growing focus on improving patient outcomes for chronic conditions such as MS, the increased healthcare expenditure is expected to fuel kesimpta's growth.

A key trend in the kesimpta market is the shift toward self-administered, targeted B-cell therapy for relapsing forms of multiple sclerosis (RMS). Kesimpta offers a convenient self-administered treatment that targets B-cells, reducing relapses and slowing disease progression in patients with RMS. For example, in April 2024, Novartis, the manufacturer of Kesimpta, released six-year efficacy data for the drug, demonstrating significant benefits for recently diagnosed, treatment-naïve individuals with RMS. This data, from the ALITHIOS open-label extension study, emphasizes the importance of early intervention in managing MS, further bolstering Kesimpta's potential as a preferred treatment option. The growing focus on self-administered therapies for chronic conditions is expected to drive Kesimpta’s adoption and market growth.

The key company operating in the kesimpta market is Novartis AG.

North America was the largest region in the kesimpta market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kesimpta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kesimpta market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kesimpta (ofatumumab) is a prescription monoclonal antibody used to treat relapsing forms of multiple sclerosis (MS) in adults. It works by targeting and depleting B-cells, which are involved in the immune system's attack on the nervous system in MS. Administered as a subcutaneous injection, Kesimpta provides a more convenient alternative to intravenous therapies. While generally well-tolerated, potential side effects include infections, headaches, and injection site reactions.

The primary indications for kesimpta include the treatment of rhabdomyosarcoma (RMS), clinically isolated syndrome (CIS), and active secondary progressive multiple sclerosis (SPMS). The treatment of RMS, a rare soft tissue cancer, typically involves a combination of surgery, chemotherapy, and radiation therapy to remove or shrink tumors and prevent recurrence. For advanced or recurrent cases, targeted therapies and clinical trials may be considered. Kesimpta is available in injectable formulations, including pre-filled syringes and autoinjectors. The patient demographics include pediatric, adult, and geriatric patients. Distribution channels include direct sales, wholesalers, retail pharmacies, and online pharmacies. It is used by various end users, such as hospitals, specialty pharmacies, home healthcare providers, and neurology clinics.

The kesimpta market research report is one of a series of new reports that provides kesimpta market statistics, including kesimpta industry global market size, regional shares, competitors with a kesimpta market share, detailed kesimpta market segments, market trends and opportunities, and any further data you may need to thrive in the kesimpta industry. This kesimpta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kesimpta market consists of sales of prefilled syringes, injection forms, and liquid solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.